Role of Capecitabine in Early Breast Cancer

Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with early-stage breast cancer still develop recurrent disease, and there is need of additional improvement of systemic therapies. Triple-negative breast cancer (TNBC) comprises approximately 15% to 20% of all…

Read the full article here

Related Articles